Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy

Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques

(2016) Philip G Conaghan et al.   ANNALS OF THE RHEUMATIC DISEASES

Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study

(2016) Munther Khamashta et al.   ANNALS OF THE RHEUMATIC DISEASES

Familial chilblain lupus due to a gain-of-function mutation in STING

(2016) Nadja König et al.   ANNALS OF THE RHEUMATIC DISEASES

Update on clinical trials in systemic lupus erythematosus

(2016) Sonali Narain et al.   CURRENT OPINION IN RHEUMATOLOGY

Quantification of risk factors for postherpetic neuralgia in herpes zoster patients

(2016) Harriet J. Forbes et al.   NEUROLOGY

Baricitinib in Patients with Refractory Rheumatoid Arthritis

(2016) Mark C. Genovese et al.   NEW ENGLAND JOURNAL OF MEDICINE

Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination

(2016) Huifeng Yun et al.   Arthritis & Rheumatology

Cigarette Smoke Induces Immune Responses to Vimentin in both, Arthritis-Susceptible and -Resistant Humanized Mice

(2016) Mitali Bidkar et al.   PLoS One

Opportunistic infections and biologic therapies in immune-mediated inflammatory diseases: consensus recommendations for infection reporting during clinical trials and postmarketing surveillance

(2015) K L Winthrop et al.   ANNALS OF THE RHEUMATIC DISEASES

LB0001 Baricitinib, an Oral Janus Kinase (JAK)1/JAK2 Inhibitor, in Patients with Active Rheumatoid Arthritis (RA) and An Inadequate Response to CDMARD Therapy: Results of the Phase 3 RA-Build Study:

(2015) M. Dougados et al.   ANNALS OF THE RHEUMATIC DISEASES

The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis

(2015) Kevin L Winthrop et al.   ANNALS OF THE RHEUMATIC DISEASES

Factors Associated With Age of Onset of Herpes Zoster Ophthalmicus

(2015) Annie Y. Chan et al.   CORNEA

Incidences of Herpes Zoster and Postherpetic Neuralgia in Japanese Adults Aged 50 Years and Older From a Community-based Prospective Cohort Study: The SHEZ Study

(2015) Yukiko Takao et al.   JOURNAL OF EPIDEMIOLOGY

Risks of Herpes Zoster in Patients With Rheumatoid Arthritis According to Biologic Disease-Modifying Therapy

(2015) Huifeng Yun et al.   ARTHRITIS CARE & RESEARCH

Herpes Zoster Reactivation in Patients With Rheumatoid Arthritis: Analysis of Disease Characteristics and Disease-Modifying Antirheumatic Drugs

(2015) Dimitrios A. Pappas et al.   ARTHRITIS CARE & RESEARCH

Effect of prednisone on type I interferon signature in rheumatoid arthritis: consequences for response prediction to rituximab

(2015) Tamarah D de Jong et al.   ARTHRITIS RESEARCH & THERAPY

Evaluation of the effect of tofacitinib on measured glomerular filtration rate in patients with active rheumatoid arthritis: results from a randomised controlled trial

(2015) Joel M Kremer et al.   ARTHRITIS RESEARCH & THERAPY

Systemic Therapy for Psoriasis and the Risk of Herpes Zoster

(2015) Guy Shalom et al.   JAMA Dermatology

Potential Mechanisms Leading to the Abnormal Lipid Profile in Patients With Rheumatoid Arthritis Versus Healthy Volunteers and Reversal by Tofacitinib

(2015) Christina Charles-Schoeman et al.   Arthritis & Rheumatology

The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis

(2014) D L Boyle et al.   ANNALS OF THE RHEUMATIC DISEASES

Psoriatic arthritis treatment and the risk of herpes zoster

(2014) D Zisman et al.   ANNALS OF THE RHEUMATIC DISEASES

Safety and Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, for the Treatment of Rheumatoid Arthritis in Open-label, Longterm Extension Studies

(2014) J. Wollenhaupt et al.   JOURNAL OF RHEUMATOLOGY

Efficacy and safety of tofacitinib as monotherapy in Japanese patients with active rheumatoid arthritis: a 12-week, randomized, phase 2 study

(2014) Yoshiya Tanaka et al.   Modern Rheumatology

Tofacitinib versus Methotrexate in Rheumatoid Arthritis

(2014) Eun Bong Lee et al.   NEW ENGLAND JOURNAL OF MEDICINE

Herpes Zoster and Tofacitinib Therapy in Patients With Rheumatoid Arthritis

(2014) Kevin L. Winthrop et al.   Arthritis & Rheumatology

Tofacitinib in Combination With Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis

(2013) Joel Kremer et al.   ANNALS OF INTERNAL MEDICINE

Open-label tofacitinib and double-blind atorvastatin in rheumatoid arthritis patients: a randomised study*

(2013) Iain B McInnes et al.   ANNALS OF THE RHEUMATIC DISEASES

Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: Twelve-month data from a twenty-four-month phase III randomized radiographic study

(2013) Désirée van der Heijde et al.   ARTHRITIS AND RHEUMATISM

Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis

(2013) Helene Che et al.   JOINT BONE SPINE

Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial

(2013) Gerd R Burmester et al.   LANCET

Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: Results of a phase I, placebo-controlled, double-blind, dose-escalation study

(2012) Jacqueline M. McBride et al.   ARTHRITIS AND RHEUMATISM

Association Between Vaccination for Herpes Zoster and Risk of Herpes Zoster Infection Among Older Patients With Selected Immune-Mediated Diseases

(2012) Jie Zhang et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Placebo-Controlled Trial of Tofacitinib Monotherapy in Rheumatoid Arthritis

(2012) Roy Fleischmann et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tofacitinib or Adalimumab versus Placebo in Rheumatoid Arthritis

(2012) Ronald F. van Vollenhoven et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incidence and Time Trends of Herpes Zoster in Rheumatoid Arthritis: A Population-Based Cohort Study

(2012) Bharath Manu Akkara Veetil et al.   ARTHRITIS CARE & RESEARCH

A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone

(2011) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs

(2011) Roy Fleischmann et al.   ARTHRITIS AND RHEUMATISM

Phase II study of tofacitinib (CP-690,550) combined with methotrexate in patients with rheumatoid arthritis and an inadequate response to methotrexate

(2011) Yoshiya Tanaka et al.   ARTHRITIS CARE & RESEARCH

The safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: Results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placebo

(2009) Joel M. Kremer et al.   ARTHRITIS AND RHEUMATISM

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

(2009) Anja Strangfeld   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION